Latest blog articles

It’s been almost a month since the COVID-19 pandemic has drastically changed the way we live and work. Now that we are more used to, in a manner of speaking, the extraordinary measures to curtail the rampant spread of the virus, it’s time to seriously consider, and openly discuss, this crisis’...

Globally the majority of health-related R&D is invested in medicines with substantial guaranteed returns, yet what is missing is extensive R&D targeted at diseases overwhelmingly prevalent in developing countries. This threatens long-term availability of medicines and treatment options for these...

​On 6 June, IGIR fellow Dr. Iveta Alexovičová, Assistant Professor of International Economic Law, Faculty of Law, Maastricht University, delivered a lecture entilted "Substance alongside procedure - a lesson learned?".